University Hospital Limerick

Futó vizsgálatok

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Forrás

• Toboroz

  Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study

  NCT07605936· Forrás

• Toboroz

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· 3. fázis· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· Forrás

• Toboroz

  A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  NCT06943872· 3. fázis· Forrás

• Toboroz

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· 3. fázis· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Forrás

• Toboroz

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Forrás

• Meghívásos bevonás

  Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

  NCT05844449· 3. fázis· Forrás

• Toboroz

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· 3. fázis· Forrás

• Toboroz

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· 3. fázis· Forrás

• Fut, nem toboroz

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· 3. fázis· Forrás

• Fut, nem toboroz

  Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

  NCT05422222· 3. fázis· Forrás

• Fut, nem toboroz

  Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

  NCT05123131· 2. fázis· Forrás

• Fut, nem toboroz

  Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

  NCT04595565· 3. fázis· Forrás

• Fut, nem toboroz

  Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

  NCT04602468· 4. fázis· Forrás

• Fut, nem toboroz

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

  NCT04002297· 3. fázis· Forrás

• Fut, nem toboroz

  Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

  NCT02804815· 3. fázis· Forrás

• Toboroz

  Breast Cancer Proteomics and Molecular Heterogeneity

  NCT01840293· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Cisztás fibrózis2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Krónikus limfoid leukémia (CLL)2 toboroz
• Prosztatarák2 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Stroke (szélütés)1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· 3. fázis· Forrás

• Fut, nem toboroz

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· 2. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· 3. fázis· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC

  NCT04191096· 3. fázis· Forrás

• Lezárult

  Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study

  NCT06274541· Forrás

• Fut, nem toboroz

  A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  NCT03522246· 3. fázis· Forrás

• Lezárult

  A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

  NCT03215706· 3. fázis· Forrás

• Lezárult

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· 3. fázis· Forrás

• Lezárult

  Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)

  NCT02504372· 3. fázis· Forrás